Lei Zhang

Dr. Lei Zhang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2020 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
Yanyu ZhangYanyu Zhang
Yanyu Zhang
YXYuan Xie
Yuan Xie
LHLiqun He
Liqun He
JTJiefu Tang
Jiefu Tang
QHQiyuan He
Qiyuan He
LZLei Zhang
Lei Zhang

24 January 2020 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
LZLei Zhang
Lei Zhang
YHYifang Huang
Yifang Huang
XGXuedong Gan
Xuedong Gan
SHSiying He
Siying He
XCXiaohuan Cheng
Xiaohuan Cheng
FZFang Zheng
Fang Zheng
Background: Atorvastatin belongs to the group of statins and is the leading drug for hypercholesterolemia treatment. Although, its anticancer effects are highly appreciated, its properties are still unclear. The aim of this study was to explore the underlying anticancer mechanisms induced by atorvastatin and enlarge the potential target in non-small cell lung cancer. Methods: arget genes of atorvastatin were collected by the DrugBank database. Prediction of interaction between primary targets and secondary targets was performed, and protein-protein interaction network was constructed though the STRING. Then, KEGG pathway enrichment analysis was performed with WebGestalt and ClueGO, including the pathways in non-small cell lung cancer. Furthermore, a genomic alteration analysis of the selected seed genes of atorvastatin benefit and non-small cell lung cancer pathway was conducted by cBioPortal. Finally, a survival analysis with the selected seed genes in lung cancer (lung adenocarcinoma, lung squamous cell carcinoma) was conducted using Kaplan-Meier (KM) plotter. Results: To identify seed genes, 65 potential candidate genes were screened as targets for atorvastatin using STRING with DrugBank database, while the KEGG pathway was enriched to get the overlap match of pathways in non-small cell lung cancer. Then 4 seed genes, Epidermal Growth Factor Receptor (EGFR), erb-b2 receptor tyrosine kinase 2 (ERBB2), AKT serine/threonine kinase 1 (AKT1) and tumor protein p53 (TP53), were selected and their genomic alternation were evaluated by cBioPortal. Survival analysis found that TP53 and EGFR showed a significant correlation (log rank P = 3e-07 and 0.023) with lung adenocarcinoma and lung squamous cell carcinoma, according to the KM analysis. Conclusion: Gene-phenotype connectivity for atorvastatin in non-small cell lung cancer was identified using functional/activity network analysis method, and our findings demonstrated that TP53 and EGFR could be the potential targets in cancer patients with atorvastatin therapy.

15 November 2025 in Surgical Oncology
Verified
Journal Article
Closed access
ZGZhengmao Ge
Zhengmao Ge
GJGuyu Jin
Guyu Jin
HWHongkang Wang
Hongkang Wang
SWShimin Wang
Shimin Wang
XFXiaowei Fei
Xiaowei Fei
Yanyu ZhangYanyu Zhang
Yanyu Zhang

1 October 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
HLHuan Liu
Huan Liu
YLYueguang Liu
Yueguang Liu
YDYixuan Dai
Yixuan Dai
LZLei Zhang
Lei Zhang
MLMei Long
Mei Long
Background: Cellular metabolic irregularities are intricately associated with the initiation and progression of tumors. Emerging evidence suggests that interactions between intratumoral microbiomes and host mediate this process. However, a comprehensive understanding of the role of metabolism-related intratumoral microbes (MRIMs) in lung adenocarcinoma (LUAD) is still lacking. This study aimed to investigate the characteristics and prognostic significance of MRIMs, as well as elucidate their potential implications in relation to the microenvironment in LUAD. Methods: Integrated analyses were conducted using accessible datasets of the microbiome, bulk and single-cell transcriptomes. Spearman’s coefficient between metabolic activity score and microbial abundance was used to identify MRIMs. An unsupervised clustering approach was utilized to distinguish the MRIMs-featured subtypes in LUAD samples. The Scissor algorithm was executed to select the cell subpopulations featured by MRIMs, and the underlying regulatory network in MRIMs-featured cells was explored. Additionally, a prognostic signature based on the microbial abundance of MRIMs was developed, and comprehensive analyses were subsequently carried out to reveal the correlation between MRIMs and LUAD microenvironment. Results: Ten microbial species were identified as MRIMs, enabling the classification of LUAD samples into two distinct subtypes that showed significantly associated with clinical features and survival outcomes. The scRNA-seq analysis revealed notable differences in T cells, ciliated cells, mast cells, endothelial cells, and fibroblasts between MRIM+ and MRIM− subpopulations. BCL3, KLF3, and NFKB2 were the regulons in the regulatory network of MRIM-featured cells. Additionally, a microbial prognostic-predictive signature was established comprising Succinimonas, Collimonas, and Marichromatium, which also exhibited potential for indicating immunotherapeutic benefit and predicting drug sensitivity to cisplatin, cytarabine, pyrimethamine, olaparib, bicalutamide and vorinostat in LUAD treatment. Conclusions: This study identified intratumoral microbes associated with metabolism, revealed distinct subtypes and their roles in LUAD, and established a predictive signature for the prognosis and therapeutic responsiveness of LUAD.

21 October 2026 in Biochemistry and Molecular Biology Education
Verified
Journal Article
Closed access
BXBing Xiao
Bing Xiao
MZMaocui Zhu
Maocui Zhu
ZLZiyi Li
Ziyi Li
SWShimin Wang
Shimin Wang
LYLuting Yang
Luting Yang
YXYuan Xie
Yuan Xie

12 May 2026 in Nature Communications
Verified
Journal Article
Open access
TCTingting Cui
Tingting Cui
YGYe Gong
Ye Gong
ZWZhen Wang
Zhen Wang
PLPei Li
Pei Li
LDLuhang Dai
Luhang Dai
YYYaping Yan
Yaping Yan
CD59 is an endogenous complement inhibitor that restricts membrane attack complex formation, protecting cells from complement-dependent cytotoxicity. Dysfunctional CD59 leads to uncontrolled complement activation and contributes to the pathogenesis of various diseases, including neuromyelitis optica spectrum disorder (NMOSD), a rare inflammatory autoimmune disorder specifically targeting astrocytes. However, the mechanisms underlying the regulation of CD59 expression are complex and need to be elucidated. Here, we show that in a clinically relevant NMOSD model using female mice, astrocytic CD59 protects astrocytes from AQP4-IgG and complement-mediated attacks. Through secretome and transcriptome analysis, we identified brain endothelial cell-derived SPARC as an inhibitor of VEGFA/VEGFR2 signaling, which suppresses astrocyte proliferation and CD59 production. Endothelial SPARC loss increases astrocytic CD59 and mitigates autoimmune astrocytopathy, whereas VEGFR2 activation induces CD59 and alleviates disease. Collectively, this study reveals how endothelial SPARC regulates astrocytic CD59 expression, promoting autoimmune astrocytopathy and providing a potential avenue for astrocyte-targeted therapies in NMOSD.